In Re Hubbell

Guest post by Theresa Stadheim of Schwegman Lundberg & Woessner)

In In Re Jeffrey Hubbell, Jason Schense, Andreas Zisch, and Heike Hall, Appeal No. 2011-1547 (Fed. Cir. March 7, 2013) (a copy can be found at the end of this post), the Federal Circuit affirmed a Board of Patent Appeals and Interferences (BPAI) decision that claims of U.S. Patent Application No. 10/650,509 (the ‘509 application”) were obvious under the doctrine of obviousness-type double patenting.

The invention disclosed in the ‘509 application was based on research by Jeffrey Hubbell and Jason Schense while they were employed at California Institute of Technology (“CalTech”).  The ‘509 application was assigned to CalTech.  Hubbell left CalTech and joined the faculty of Eidgenossische Technische Hochschule Zurich (“ETHZ”) five years before the ‘509 application was filed.  An application that later issued as patent number 7,601,685 (“the ‘685 patent”) was based on research by Hubbell and Schense at ETHZ.  The ‘695 patent was assigned to ETHZ and Universitat Zurich.  The ‘509 application was rejected by the Examiner for obviousness-type double patenting over the ‘685 patent and other patents.  (A copy of the ‘509 application as published and the ‘685 patent can be found at the end of this post).  The BPAI affirmed the rejection, rejecting Hubbell’s argument that common ownership is required for obviousness-type double patenting.

Continue reading

Posted in Double Patenting | Tagged , , , , , , , , , , , | Leave a comment

Federal Circuit Will Review Cybor Decision En Banc

On March 15th, in a long-awaited ruling, the Fed. Cir. vacated a panel holding reversing a lower court’s finding that disputed means-plus-function claims met the written description requirement. The Fed. Cir. asked the parties and amici (and there will be many of them) to address the position adopted in the Cybor decision that interpretations of claim  meaning and scope by a lower court are questions of law that are properly reviewed de novo by the Fed. Cir. without giving any deference to the fact-finding made by the lower court in support of its decision.

District Courts have long chafed under this decision since they are required to do all the work required to conduct a Markman hearing that may ultimately be completely disregarded by the Fed. Cir. when it reviews verdicts turning on claim construction–as most of them must. However, should even precise fact-finding trump basic rules of claim construction? The outcome of this en banc decision will be as important to patent law as KSR, Markman and Philips defined. In any case, that is what the scholars will be telling us for a year or two to come.

En Banc Order

Posted in Claim Interpretation | Tagged , , , , | Leave a comment

UK National Stem Cell Network Report – The Patent Watch Landscape

If you have either a passing or passionate interest in stem cell patenting, this report is worth some of your time. (A link to the report can be found at the end of this post.)

The report analyzes the stem cell patent landscape from November 2008 to Oct 2009 and from November 2008 to October 2011. The “patent watch dataset” is based on patent applications published or patents issued/ granted by the PCT and in the US, EP and  UK. The top applicant of published applications is Kyoto University and the top applicant on granted patents is WARF.

However, the report goes far beyond a simple numbers game; it analyzes the therapeutic areas of research represented by the stem cell IP. The report provides topography maps of the various areas such as pluripotent cells (e.g., embryonic stem cells) that is still a very active area, as is research in the areas of hematopoietic stem cells and neural stem cells. Even more interesting is the analysis that maps collaborations between high-filing universities and their spin-offs or start-up companies, as well as established companies.

Having done some of the early IP work on pluripotent adult stem cells, I found the report as addictive as a box of chocolates – I never was sure what would be on the next page.

informatic-stemcells

Posted in Stem Cells/Cloning | Tagged , , , , , , , , , | Leave a comment

Deposit of Biological Material – Impact on Validity of Priority Claim

Please find linked below a guest post from Dr. Stefan Danner dealing with a new decision of the EPO Technical Boards of Appeal concerning the deposit of biological material.

Biotech IP Newsletter

 

Posted in Int'l Practice and Policy | Tagged , , , , , | Leave a comment